Table 3 Antibiotic resistance rate according to regions determined by WHO
WHO region | Single-antibiotic resistance | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
AMX | MTZ | TET | CLA | LEV | ||||||
Rate, % | 95% CI | Rate, % | 95% CI | Rate, % | 95% CI | Rate, % | 95% CI | Rate, % | 95% CI | |
Americas | 7.1 | (5.1–9.9) | 43.1 | (38.6–47.7) | NA | NA | 23.5 | (14.1–36.5) | NA | NA |
Eastern Mediterranean | 37.4 | (10.4–75.5) | 55.6 | (33.0–47.3) | 5.3 | (1.1–22.2) | 22.3 | (10.4–41.5) | NA | NA |
European | 2.2 | (1.0–4.7) | 25.2 | (21.0–29.9) | 1.8 | (1.1–2.9) | 28.0 | (22.1–34.7) | 4.2 | (2.2–8.0) |
Western Pacific | 5.5 | (1.8–15.5) | 46.9 | (36.0–58.1) | 4.1 | (1.9–8.5) | 49.1 | (38.0–60.2) | 22.0 | (14.4–31.9) |
| Â | Multi-antibiotic resistance | |||||||||
CLA + LEV | MTZ + CLA | MTZ + LEV | CLA + MTZ + LEV | |||||||
Rate, % | 95% CI | Rate, % | 95% CI | Rate, % | 95% CI | Rate, % | 95% CI | |||
European | NA | NA | 12.8 | (9.0–17.8) | NA | NA | 2.3 | (1.1–4.8) | ||
Western Pacific | 2.7 | (0.5–13–6) | 13.0 | (9.5–17.6) | 5.1 | (2.1–11.5) | 7.5 | (6.8–8.3) | ||